Overview

Dose-escalation Study of IMC-001 in Subject With Metastatic or Locally-advanced Solid Tumors

Status:
Completed
Trial end date:
2020-05-14
Target enrollment:
Participant gender:
Summary
This is a phase 1, Open-label, Multiple-ascending Dose Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of IMC-001 in Subjects with Metastatic or Locally-advanced Solid Tumors
Phase:
Phase 1
Details
Lead Sponsor:
ImmuneOncia Therapeutics Inc.